Akari Therapeutics, Plc
AKTX · NASDAQ
Bulios Fair Price
$11.79
31.9% upside
Trenutna cena
$8.94
Po podatkih Bulios Fair Price je delnica AKTX trenutno podcenjena glede na svojo tržno ceno. Kako deluje?
Bulios Fair Price je ocena poštene vrednosti delnice iz Buliosovega modela vrednotenja. Je vhod za vašo lastno analizo, ne naložbeno priporočilo. Kako deluje?
AI poročilo o poslu, financah, vrednotenju, razpoloženju, novicah in tveganjih - napisano v nekaj minutah.
Bulios Scoring opisuje kakovost in preteklost podjetja, ne prihodnjega donosa. Visok rezultat ni nakupni signal. Izvedite več
O podjetju
Akari Therapeutics, Plc (AKTX) is a biopharmaceutical company focused on developing therapies for the treatment of inflammatory diseases and autoimmune disorders. The company's main focus is on researching and developing complement inhibition-based therapies, which play a key role in the body's immune response. One of the company's main products is Nomacopan (also known as Coversin), which is being developed for the treatment of various diseases, including paroxysmal nocturnal hemoglobinuria (PNH) and other autoimmune disorders. Akari Therapeutics, Plc aims to bring innovative therapeutic solutions to patients with diseases that have not been adequately addressed by existing treatments. Shares of Akari Therapeutics, Plc (AKTX) could be suitable for investors who are tracking the biotechnology sector and seeking opportunities in the development of drugs for inflammatory diseases and autoimmune disorders.
V vašem jeziku še ni na voljo, zato je besedilo v angleščini.
Sector
Healthcare
Industry
Biotechnology
CEO
Abizer Gaslightwala
Employees
6
Headquarters
Tampa
Prihajajoči dogodki
Earnings
Upcoming earnings report